Cellular immunotherapy specialist Fate Therapeutics (Nasdaq: FATE) was more than 50% down in Friday’s pre-market trading.
This followed the US company’s announcement that it has declined a proposal from the Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Biotech for continuation of the collaboration and option agreement between the parties on revised terms and conditions.
As a result, the agreement has been terminated and all collaboration activities will be wound down in the first quarter of 2023.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze